Table 2.
Patient cohort | POD24-PI | FLIPI | m7-FLIPI | PRIMA-PI | FLEX | |||||
---|---|---|---|---|---|---|---|---|---|---|
% | Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity |
GLSG Jurinovic et al. [33] |
78 | 67 | 78 | 56 | 61 | 79 | – | – | – | - |
BCCA Jurinovic et al. [33] |
61 | 73 | 70 | 58 | 43 | 86 | – | – | – | - |
PRIMA Huet et al. [47] |
54 | 72 | 60 | 62 | 46 | 77 | – | – | – | - |
GALLIUM Mir et al. [48] |
– | – | 53a | 59a | – | – | 69 | 47 | 60 | 68 |
BCCA British Columbia Cancer Agency, FL follicular lymphoma, FLIPI Follicular Lymphoma International Prognostic Index, GLSG German Low-Grade Lymphoma Study Group, PI Prognostic Index, POD24 progression of disease within 24 months
aFLIPI and FLIPI-2